{"entity":{"id":"cbb-120","kind":"drug","name":"CBB-120","aka":[],"tldr":"CBB-120 is an experimental drug designed to carry chemotherapy to cancer cells. Its published evidence is from laboratory and animal studies.","summary":"AACR-NCI-EORTC 2025 abstract A124 describes CBB-120 with EGCit linkers and TOP1/ATR inhibitor payloads. Evidence includes cell assays, xenografts and cynomolgus-monkey toxicology. Tumor regressions and comparisons with single-payload ADCs were in models, not a randomized clinical comparison. On-target skin toxicity was observed in monkeys; clinical benefit and safety remain unestablished.","status":"preclinical","asOf":"2026-10-06","links":[{"label":"Publisher abstract","url":"https://doi.org/10.1158/1535-7163.targ-25-a124"}],"tags":["evidence:preclinical"],"related":[],"cancers":[],"sections":[],"technologies":["adc","dual-payload-adc"],"targets":["trop2"],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"modality":"ADC","payload":"TOP1 inhibitor plus ATR inhibitor","mechanism":"Site-specific, Fc-silenced anti-TROP2 ADC delivering a TOP1 inhibitor and an ATR inhibitor to combine DNA damage with inhibition of its repair.","approvals":[],"mechanismSteps":[],"toxicity":[],"access":[],"regulatoryEvents":[]},"route":"/drugs/cbb-120/","neighbours":{"technology":[{"id":"adc","kind":"technology","name":"Antibody-drug conjugate (ADC)","route":"/technologies/adc/"},{"id":"dual-payload-adc","kind":"technology","name":"Dual-payload ADC","route":"/technologies/dual-payload-adc/"}],"target":[{"id":"trop2","kind":"target","name":"TROP2","route":"/targets/trop2/"}]}}